Posted by Michael Wonder on 08 Apr 2024
Stealth BioTherapeutics announces FDA acceptance of new drug application for elamipretide for the treatment of Barth syndrome
8 April 2024 - If approved, elamipretide would become the first approved therapy for Barth syndrome.
Stealth BioTherapeutics today announced that the US FDA has accepted for filing its new drug application for elamipretide for the treatment of Barth syndrome.
